Introduction
The development of a safe and effective vaccine against HIV infection is a global public health priority. Epidemiological data suggest that more than 75% of HIV infections world-wide are acquired through heterosexual intercourse [1] . Because parenterally administered, attenuated and killed vaccines have not been shown to prevent vaginal simian immunodeficiency virus (SIV) transmission [2] , efforts to elicit local immunity by using different routes of immunization have intensified. Numerous investigators have reported the presence of anti-HIV and SIV antibodies in the genital tract secretions of infected women [3] [4] [5] and female rhesus macaques [6] . In addition, antiviral cytotoxic T lymphocytes have been demonstrated in the cervicovaginal mucosa of SIV-infected monkeys [7] and HIVinfected women [8] . These findings demonstrate that the full range of HIV/SIV-specific immune responses can be found in the female genital tract.
Live-attenuated SIV administered intravenously can protect macaques from intravenous challenge with pathogenic SIV [9] . However, studies to date in animals and humans have not identified the correlates of immune protection [10] . Intravaginal immunization with an attenuated simian-human chimeric immunodeficiency virus protects rhesus macaques from intravaginal challenge with pathogenic SIV [11] . Because protective rectal mucosal immunity in macaques is elicited by a targeted iliac lymph-node (TILN) immunization with a subunit SIV envelope and core vaccine [12] , we sought to determine whether TILN immunization strategy with whole inactivated SIV or SIV subunits could protect animals from vaginal challenge with SIV mac251 .
Materials and methods

Animals
All animals used in this study were captive-bred, multiparous, cycling female rhesus macaques (Macaca mulatta) from the California Regional Primate Research Center. Prior to their initial use, the animals were negative for antibodies to HIV-2, SIV, type D retrovirus, and simian T-cell leukemia virus type 1. The animals were housed in accordance with American Association for Accreditation of Laboratory Animal Care standards. When necessary, the animals were immobilized with 10 mg/kg ketamine HCl (Parke-Davis, Morris Plains, New Jersey, USA), which was injected intramuscularly.
Immunogens and route of immunization
The whole inactivated SIV vaccine consisted of sucrose gradient-purified SIV mac251 that was inactivated with βpropiolactone, as described previously [13] . The origin of the recombinant SIV mac251 gp120 and recombinant SIV p27 has been previously described [14] . SIV mac251 Pr55 and SIV mac239 gp130 were obtained from Quality Biological, Inc. (Gaithersburg, Maryland, USA), and were produced under contract no. N01-AI-05084 of the Vaccine Research and Development Branch (Division of AIDS, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, USA). For all immunizations, an aqueous solution of aluminum hydroxide (Imject Alum, Pierce, Rockford, Illinois, USA) was used as the adjuvant.
All immunizations were performed using the TILN procedure [12] . Briefly, TILN immunization was performed by subcutaneous injection. The needle was first inserted to a depth of 1-2 cm medially to the femoral pulse just above the inguinal ligament, dispensing about 0.15 ml. The needle was then directed at a depth of 4 cm upwards and laterally toward the pelvic floor where the rest of the vaccine (about 0.35 ml) was injected after the needle tip was in the posterior wall of the pelvis. This procedure was performed bilaterally each time. Because this technique involved blind placement of the needle into the posterior wall of the pelvic cavity and the internal anatomy of each animal was variable, it was impossible to be certain that the antigen was identically placed at each immunization. It is important to note that the lymphatic drainage of the posterior wall of the pelvis is directed to the iliac lymph nodes [15] .
Immunization protocols
The experiment included five groups of animals ( Table 1 ). The initial study included three groups: two vaccine groups (A and B), and one naive control group (C). Subsequently, two groups [one vaccine group (D) and one control group (E)] were added to the experiment. In group A, three monkeys (22575, 24331 and 25428) were immunized with inactivated whole SIV (200 µg). In group B, three monkeys (21747, 24428 and 24816) were immunized with SIV gp120 (200 µg) and p27 (200 µg). Animals in groups A and B were immunized at 0, 4 and 8 weeks. Intravaginal challenge with SIV mac251 was performed at 10 weeks. Serum samples, cervicovaginal secretions (CVS) and rectal secretions were collected at multiple timepoints. In group C, four macaques (25255, 25422, 24803 and 25597) were used as naive controls and were intravaginally challenged with SIV mac251 at the same time as groups A and B.
In group D, three monkeys (20634, 22212 and 22590) were immunized with subunit recombinant SIV mac251 Pr55gag (200 µg) and SIV mac239 gp130 (200 µg) at 0, 5, 8 and 14 weeks. Intravaginal challenge with SIV mac251 was performed at 17 weeks. This choice of antigen was dictated by the limited availability of the SIV subunit antigens used in group B. Serum samples and CVS were collected at multiple timepoints. Group E comprised two naive monkeys (26665, 26742) that served as controls and were intravaginally challenged with SIV mac251 at the same time as group D.
Sample collection
Peripheral blood was collected by venipuncture into heparinized tubes (for cell isolation) or into nonheparinized tubes (for serum). Vaginal washes consisted of a mixture of cervical and vaginal secretions and were collected by vigorously infusing 6 ml sterile phosphatebuffered saline into the vaginal canal and aspirating as much of the instilled volume as possible. Care was taken to insure that the cervical mucus was bathed in the lavage fluid and that no trauma to the mucosa occurred during the procedure. The samples were snap-frozen on dry ice and stored at −80°C until analysis. For analysis, the samples were thawed, centrifuged at 5000 r.p.m. in a microcentrifuge for 10 min and the supernatant was collected. Neomycin sulfate (200 µg/ml; ICN Biomedical, Inc., Aurora, Ohio, USA) and a cocktail (10% vol/vol) of protease inhibitors [0.6 mM 4-(2-aminoethyl) benzenesulfonyl fluoride, 3 µg/ml aprotinin, 30 µM leupeptin, 9.75 µM bestatin; Sigma Chemical Co., St Louis, Missouri, USA] was added to the supernatant and the enzymelinked immunosorbent assay (ELISA) was performed as described below. It was estimated that the sample collection and preparation procedure resulted in at least a 10-fold dilution of the CVS. Rectal washings were collected without trauma, with the aid of flexible, lubricated pediatric nasogastric tubes and processed in the same manner as the CVS samples.
Antibody ELISA assays
Prior to determining antibody titers, sera and vaginal secretions were screened for the presence of anti-SIV antibodies using a 1 : 100 dilution of sera and a 1 : 4 dilution of vaginal washes or rectal washes in the same ELISA assay protocol used to determine antibody titers, described below. Results of the screening assay were calculated using the following ratio: change in optical density (∆OD)/cut-off (CO), where ∆OD is defined as the difference between the mean OD of a dilution of sample tested in two antigen-coated wells and the mean OD of the same dilution of sample tested in two antigen-free (control) wells. The cut-off (CO) value is the mean ∆OD + 3 SD of duplicate wells containing sera or vaginal washes from 12 randomly selected seronegative adult female rhesus macaques. If the ∆OD/CO ratio for a sample was greater than 2.0, the sample was considered to be positive.
An additional analysis was used to determine anti-SIV antibody titers in antibody positive serum, CVS, and rectal washes. Ninety-six-well microtiter plates (Nunc Immunoplate II Maxisorp, Applied Scientific, South San Francisco, California, USA) were coated with whole pelleted SIV mac251 (Advanced Biologics, Inc., Columbia, Maryland, USA) at 5 µg/ml in 0.1 M Na 2 CO 3 /NaHCO 3 buffer (pH 9.6) and blocked with 4% non-fat powdered milk. Plasma and vaginal wash samples were serially diluted (1 : 4) in duplicate and the plates were incubated overnight at 4°C. The initial dilution of serum was 1 : 10 000 for SIV-specific immunoglobulin (Ig) G assay and 1 : 1000 for SIVspecific IgA assay. Antibody binding was detected using a 1 : 2000 dilution of peroxidase-conjugated goat anti-monkey IgG(Fc) (100 µl per well) or 1 : 1000 peroxidase-conjugated goat anti-monkey IgA(Fc) (100 µl per well; Nordic Laboratories, San Juan Capistrano, California, USA) for 1 h at 37°C. Plates were developed with o-phenylenediamine dihydrochloride (Sigma Chemical Co.) for 5 min and stopped with H 2 SO 4 before reading the OD at 490 nm. For each serum or vaginal/rectal wash sample, the endpoint titer of anti-SIV antibodies was defined as the reciprocal of the last dilution giving a ∆OD value greater than 0.2, where ∆OD was defined as the difference between the mean OD of two antigen-coated and two antigen-free (control) wells.
Virus isolation
Virus was isolated from heparinized whole blood obtained from the SIV-inoculated rhesus macaques. Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll gradient separation medium (Lymphocyte Separation Medium, Organon Teknika, West Chester, Pennsylvania, USA) and cocultured with CEM-X174 cells as previously described [11] . Five million PBMC were cocultivated with 2-3 million CEM-X174 cells. Aliquots of the culture media were assayed regularly for the presence of SIV major core protein (p27) by an antigen capture ELISA [16] . Cultures were considered positive if they were antigenpositive at two consecutive timepoints. A detailed description of the technique and criteria to determine whether culture media was antigen-positive has been previously published [17] . All cultures were maintained for 8 weeks before being scored virus-negative. Blood samples for virus isolation were collected at 1, 2, 4, 6, 8, 12, 16, 20, 24 and 28 weeks post-challenge.
Polymerase chain reaction-based detection of SIV proviral DNA sequences
The sequences of the nested primer pairs used to detect SIV gag have been previously described [11] . Nested polymerase chain reaction (PCR) was carried out on genomic PBMC DNA in a DNA Thermal Cycler (Perkin-Elmer Cetus, Emeryville, California, USA) using a modification of a previously described technique [18] . Briefly, cryopreserved PBMC isolated from whole blood were washed three times in Tris buffer at 4°C and resuspended at 10 7 cells/ml. Ten microliters of the cell suspension were added to 10 µl PCR lysis buffer (50 mM Tris-HCl, pH 8.3, 0.45% Nonidet P-40, 0.45% Tween-20) with 200 µg/ml proteinase K. The cells were incubated for 3 h at 55°C, followed by 10 min at 96°C. Two rounds of 30 cycles of amplification were performed on aliquots of plasmid DNA containing the complete genome of SIV mac1A11 (positive control) or aliquots of cell lysates using conditions described elsewhere [18] . DNA from uninfected CEM-X174 cells was amplified as a negative control in all assays to monitor potential reagent contamination. Using the primers listed previously [11] , β-actin DNA sequences were amplified with two rounds of PCR (30 cycles per round) from all PBMC lysates to detect potential inhibitors of Taq polymerase in cell lysates. Following the second round of amplification, a 10 µl aliquot of the reaction product was removed and run on a 1.5% agarose gel. Amplified products in the gel were visualized by ethidium bromide staining. Blood samples for PCR analysis were collected at 1, 2, 4, 8, 12, 16 and 20 weeks post-challenge.
Branched DNA quantification of plasma SIV RNA
Quantitative assays for the measurement of SIV RNA were performed using a branched DNA signal amplification assay specific for SIV [19] . This assay is similar to the Quantiplex HIV RNA assay [20] except that target probes were designed to hybridize with the pol region of the SIV mac group of strains including SIV mac251 . SIV pol RNA in plasma samples were quantified by comparison with a standard curve produced using serial dilutions of cell-free SIV-infected tissue culture supernatant. The quantification of this standard curve was determined by comparison with purified, quantified, in vitro-transcribed SIV mac239 pol RNA. SIV RNA associated with viral particles was measured after being pelleted from 1 ml heparinized plasma (23 500 g for 1 h at 4°C). The lower quantification limit of this assay was 10 000 copies of SIV RNA per ml plasma.
Results
Anti-SIV immune responses at the time of challenge
In groups A, B and D, a total of nine animals were TILN-immunized with either whole inactivated SIV or SIV subunit antigens ( Table 1) . All immunized macaques, irrespective of the vaccine, developed serum IgG and IgA antibodies to SIV mac251 by the third immunization ( Fig. 1 ). Most animals had high titers of IgGspecific antibodies in serum within 4 weeks of the first TILN immunization. After the second immunization (week 4), most animals had consistently high titers of anti-SIV IgG antibodies which remained high after the third immunization (Fig. 1) . The peak titers of IgG antibodies in serum ranged from 10 5 to 10 7 . These were the highest IgG antibody titers achieved with any immunization procedure of rhesus macaques in our laboratory. All immunized animals developed serum IgA antibody responses by the last immunization. The IgA antibody titers were also high ranging from 10 2 to 10 5 .
All immunized macaques, irrespective of vaccine preparation, had detectable SIV-specific antibodies in CVS after the last TILN immunization, except animal 24816, which had neither SIV-specific IgG nor IgA antibodies in CVS (Fig. 2) . Anti-SIV IgG antibody in rectal washes was present in group A animals after the last boost. In group B, anti-SIV IgG was detected in rectal washes of one animal at one timepoint. No IgA anti-SIV antibody was detected in either group A or B (Fig. 3) . Anti-SIV antibodies in the rectal washes from group D animals were not assessed. 
Virus isolation after intravaginal challenge
The challenge inoculum consisted of 1 ml SIV mac251 propagated in rhesus macaque PBMC (10 5 median tissue culture infective doses) delivered via a tuberculin syringe into the vaginal canal. Two doses of the virus inoculum were given to each animal with a 4 h interval between the inoculations. After challenge, virus isolation was performed at timepoints indicated in Table 1 . All control animals became virus isolation-positive, although one animal (26665) was virus isolation-positive at only one timepoint ( Table 1) . All immunized animals, except for 24816 in group B, became virus isolation-positive. Animals 24331 in group A, 24428 in group B, and 20634 and 22212 in group D were killed at the times noted in Table 1 . At necropsy, mononu-clear cells obtained from the spleen, inguinal, iliac and axillary lymph nodes of these animals were virus isolation-positive. We found that one macaque (24816, group B) remained virus isolation-negative after challenge. However, SIV gag DNA was detected in PBMC from this animal ( Table 2) . Thus, TILN immunization did not reliably protect rhesus macaques from intravaginal challenge with SIV mac251 .
PCR-based detection of SIV gag DNA from PBMC
PCR amplification of proviral DNA from PBMC was performed at the timepoints indicated in Table 2 . After SIV mac251 challenge, SIV gag DNA was detected in the PBMC of all immunized animals at all timepoints tested. One control animal (26665) was PBMC proviral DNA-positive at only two timepoints ( Table 2 ). The result of proviral SIV gag detection was consistent with the virus isolation results in all animals except 24816. Animal 24816 was virus isolation-negative but PBMC SIV gag DNA-positive. Apparently, the CD4+ cells from this animal (24816) had integrated proviral DNA but there was no detectable infectious virus in PBMC. This may have been due to the presence of defective SIV provirus in the PBMC or effective suppression of virus replication. Branched DNA quantification of plasma SIV RNA Plasma SIV pol RNA was quantified by the branched DNA assay from the day of challenge until 17 weeks post-challenge ( Fig. 4 ). In the naive control animals (group C and E), except animal 26665, a distinct peak of plasma SIV pol RNA was observed within 4 weeks after vaginal challenge. Peak levels of approximately 10 7 viral RNA copies/ml of plasma were observed in these samples. Five weeks post vaginal challenge, plasma viral RNA was detected in plasma at high levels (from 10 6 to 10 8 
Anti-SIV immune responses after intravaginal SIV mac251 challenge
All immunized animals in group A , B and D with the exception 24816 in group B maintained high sera IgG antibody titers for more than 15 weeks post-challenge. This antibody pattern is characteristic of an ongoing immune response. It should be noted that serum anti-SIV IgG progressively declined to negative levels in animal 24816 (Fig. 1 ). This animal was virus isolationnegative (Table 1) , and this antibody response pattern was consistent with lack of a productive virus infection. Serum anti-SIV IgA antibody in group A and animal 21747 in group B were also maintained at high levels after intravaginal SIV mac251 challenge. However, two animals (24816 and 24428) in group B and animals in group D had a transient pattern of serum IgA antibody, and serum IgA antibodies declined to undetectable levels at 4-8 weeks post-challenge ( Fig. 1 ).
All immunized animals in groups A, B and D, except 24816 and 24428 (group B), had anti-SIV IgG and IgA antibodies in CVS at one or two timepoints postchallenge. Animal 24816 had no detectable anti-SIV IgG or IgA antibody in CVS after intravaginal challenge (Fig. 2 ).
Discussion
Eight out of nine rhesus macaques immunized with a variety of SIV antigens by the TILN route became virus isolation-positive after vaginal challenge with pathogenic SIV mac251 . Rhesus macaques immunized by the TILN route had very high IgG and IgA-specific antibody titers in serum (10 5 to 10 7 for IgG; 10 2 to 10 5 for IgA), although serum IgG antibody levels were considerably higher than IgA levels. Prior to SIV challenge, eight out of nine animals in this study had anti-SIV-specific IgG in vaginal secretions and six out of nine animals had anti-SIV IgA in vaginal secretions. After challenge, one animal (24816) remained virus isolation-negative, but was consistently SIV gag DNApositive and was plasma SIV RNA-positive at one timepoint. We do not know whether the inability to isolate virus in this animal was due to the immune responses induced by the immunization procedures, although prior to challenge this animal did not have detectable anti-SIV IgG or IgA in vaginal secretions. In this experiment, TILN immunization did not reliably protect rhesus macaques from intravaginal challenge with SIV mac251 . The emphasis in AIDS vaccine development has shifted from eliciting sterilizing immunity to inducing immune responses that can reduce postchallenge viral load and delay progression to clinical disease, and this has been achieved in the SIV/macaque model [21] . With one exception (animal 24816), there was no evidence that animals immunized by TILN route in this study had decreased virus load after vaginal challenge.
An analysis of the patterns of cytokine secretion by the CD4+ T cells of the immunized animals in group A and B has been published as a separate report [22] , but the results will be briefly summarized here. Following the second immunization, CD4+ T cells from all the animals had a T-helper (TH)-1 pattern of cytokine secretion [interferon (IFN)-γ > interleukin (IL)-4] after PBMC were pulsed with SIV antigens in vitro. After the third immunization, the antigen-specific cytokine pattern shifted to a TH2 pattern (IL-4 > IFN-γ) in five out of six animals. One animal (24816) maintained a TH1 cytokine profile at the time of challenge. This animal had no anti-SIV antibodies in secretions but did have significant anti-SIV IgG titers in serum. Significantly, this animal remained virus isolation-negative after vaginal challenge with SIV mac251 and may thus have been able to effectively suppress virus replication. The result in this animal provides support for the idea that TH1 immune responses are desirable for HIV-1 vaccines.
It has been shown that TILN immunization with a subunit SIV envelope and core vaccine protected rhesus macaques from intrarectal challenge with SIV mac32HJ5 molecular clone [12] . Four out of seven macaques were protected from infection. The remaining three macaques had either a decrease in viral load or transient viremia [12] . The difference in the results of the vaginal and rectal challenge studies may be related to differences in (i) the virulence of the challenge virus, (ii) antiviral immunity at the rectal and vaginal mucosal surfaces, and (iii) virus transmission and dissemination at the two mucosal surfaces. SIV mac251 used in vaginal challenge is more virulent in rhesus macaques than the SIV mac32HJ5 clone. In a study comparing the two viruses directly, it was shown that animals infected with SIV mac32HJ5 were less likely to develop AIDS than animals infected with SIV mac251 [23] .
Induction of effective humoral and cellular antiviral immune response is likely to be essential for a vaccine against sexually transmitted HIV. Furthermore, vaccineinduced production of non-specific antiviral effector molecules such as chemokines, IFN or other antiviral factors may be important for protection against HIV. Antibodies present in local secretions and specific cytotoxic T lymphocytes in mucosal tissues comprise the first line of immune defense to prevent viral dissemination and subsequent systemic infection. A successful vaccine must provide excellent protective immunity in the local mucosa to prevent subsequent systemic infection. The route of administration of immunogens to induce protective anti-SIV/HIV mucosal immunity is an important issue. Our results indicate that immunization by the TILN route failed to reliably protect macaques from vaginal challenge with SIV mac251 . In our experiment, one macaque (24816) was virus isolationnegative and SIV gag DNA-positive after intravaginal SIV mac251 challenge, and this animal maintained a TH1 CD4+ T-cell response to the immunization protocol.
We have previously shown that it is possible to protect rhesus macaques from vaginal challenge with SIV by immunizing the genital tract with a live attenuated virus [11] . We believe that protection from HIV sexual transmission may be possible by using immunization strategies that simulate the immune responses elicited by attenuated virus infection.
